Gene Mack - 06 Jan 2025 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role
CEO, President, Director
Signature
/s/ Gene Mack
Issuer symbol
GANX
Transactions as of
06 Jan 2025
Transactions value $
$0
Form type
4
Filing time
07 Jan 2025, 21:00:08 UTC
Previous filing
12 Aug 2024
Next filing
21 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GANX Stock Option (right to buy) Award $0 +271,325 $0.000000 271,325 06 Jan 2025 Common Stock 271,325 $2.44 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option shall vest as to 25% on January 6, 2026 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.